Research Physicians Network — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$74,105	4
2024	Research	$119,465	8
2023	Research	$159,858	14
2022	Research	$44,677	1
2021	Research	$46,566	10
2020	Research	$36,370	11
2019	Research	$68,024	11

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $247,316 23 payments
AstraZeneca Pharmaceuticals LP $153,230 6 payments
Regeneron Pharmaceuticals, Inc. $89,659 23 payments
GlaxoSmithKline, LLC. $31,609 4 payments
AstraZeneca UK Limited $16,850 1 payment
Otsuka Pharmaceutical Development & Commercialization, Inc. $9,500 1 payment
Celgene Corporation $900 1 payment

Studies the money was for Research payments · program years 2019–2025

Transmission Study Household $247,316 23 payments
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS $126,963 2 payments
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations $89,659 23 payments
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multic $20,625 2 payments
A Phase 2, Randomised, Double-Blind, Placebo and Active Comparator-Controlled Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD5718 Given Orally Once Daily for Twelve Weeks in Adults with Moderate-to-Severe Uncontrolled Asthma $16,850 1 payment
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure $14,250 1 payment
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $11,539 1 payment
A 28-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Grou $10,984 2 payments
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Trial to Assess the Efficacy and Safety of Orally Administered Ops-2071 for 12 Weeks in Subjects With Crohns Disease Showing Symptoms of Active Inflammation Despite Ongoing Treatment $9,500 1 payment
Ph III Yellowstone CD OLE (RPC01-3204) (BMS Study Number: IM047-P17) $900 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.